Press Releases

MOBILE, Ala.--(BUSINESS WIRE)-- TruBridge, LLC, a subsidiary of CPSI (NASDAQ: CPSI) announced today that it has been recognized as the top-ranked provider for End-to-End Revenue Cycle Management (RCM) Software Technology and RCM Outsourcing Services for hospitals under 100 beds by Black Book Research. This follows rankings at number two and number five, respectively, in the Black Bo

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter ended September 30, 2018 financial results on Wednesday, November 7, 2018. Following distribution of the earnings release

BOISE, Idaho--(BUSINESS WIRE)-- The Idaho Small Business Development Center (www.idahosbdc.org), will offer two free informational sessions about the funds that are available

SOUTH PORTLAND, Maine--(BUSINESS WIRE)-- WEX Inc. (NYSE:WEX), a leading provider of corporate payment solutions, today reported financial results for the three months ended September 30, 2018. Third Quarter 2018 Financial Results Total revenue for the third quarter of 2018 increased 18% to $382.7 million from $324.0 million for the third quarter of 2017. Of the $58.7 mil

ARLINGTON, Va.--(BUSINESS WIRE)-- Graham Holdings Company (NYSE: GHC) today reported net income attributable to common shares of $125.1 million ($23.28 per share) for the third quarter of 2018, compared to $24.8 million ($4.42 per share) for the third quarter of 2017. The results for the third quarter of 2018 and 2017 were affected by a number of items as described i

SANTA MONICA, Calif.--(BUSINESS WIRE)-- PatientPop, the market leader in practice growth technology, today announced it has

WEBSTER, Texas--(BUSINESS WIRE)-- Ansh Labs announced today that it received clearance from U.S. Food and Drug Administration (FDA) for the de novo application of its Anti-Müllerian (AMH) assay kit, picoAMH, which is sold under the trademark MenoCheck®. The assay kit is intended for use as an aid in the determination of menopausal status in women between 42 and 62 years of age. This is the

BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2018. For the quarter ended September 3

SAN DIEGO--(BUSINESS WIRE)-- Synergy Wound Technology, a product development company specializing in wound management and prevention, today announced the ma

WESTLAKE, Ohio--(BUSINESS WIRE)-- TravelCenters of America LLC (TravelCenters), operator of the TA® and Petro Stopping Centers® travel center brands, announced today that its annual campaign for the St. Christopher Truckers Development and Relief Fund (SCF) has concluded for 2018. The customer and employee support received during the annual “Band Together for SCF&rdqu

TORONTO--(BUSINESS WIRE)-- FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic R&D partner, SciCann Therapeutics (“SciCann”). The study is designed to test the safety and efficacy of SciCann’s proprietary “Steady Stomach&rd

WHITE PLAINS, N.Y.--(BUSINESS WIRE)-- Fortistar LLC, a sustainability-focused private company helping to facilitate the transition to a carbon-free economy, will celebrate a successful and productive 20 year public–private partnership in providing clean, sustainable and reliable power from its Miramar landfill gas projects at a landfill event on November 4th, kicking off the U.S. Biogas 2018 conference in

LINCOLN, Neb.--(BUSINESS WIRE)-- Celerion, a leader in early clinical research, is pleased to announce the implementation of

NEW YORK--(BUSINESS WIRE)-- Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, today announced it has treated the first patient in a Phase 1 a/b study of RGX-202, an oral small molecule being developed for the treatment of gastrointestinal cancers. RGX-202 is the second clinical stage therapeutic in development at Rgenix.

BOSTON--(BUSINESS WIRE)-- PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced that the Company has launched a new China Advisory Service to help global biopharmaceutical companies participate in the growing, yet complex market opportunity within China. The offering leverages PAREXEL’s deep experience with and knowledge of the Chinese biopharmaceutic